DK2805723T3 - Cladribin-regime til behandling af multipel sclerose - Google Patents
Cladribin-regime til behandling af multipel scleroseInfo
- Publication number
- DK2805723T3 DK2805723T3 DK14001970.4T DK14001970T DK2805723T3 DK 2805723 T3 DK2805723 T3 DK 2805723T3 DK 14001970 T DK14001970 T DK 14001970T DK 2805723 T3 DK2805723 T3 DK 2805723T3
- Authority
- DK
- Denmark
- Prior art keywords
- multiple sclerosis
- treatment
- cladribine
- regimen
- cladribine regimen
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title abstract 2
- 229960002436 cladribine Drugs 0.000 title abstract 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP10182676.6A EP2263678B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating early secondary progressive Multiple Sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2805723T3 true DK2805723T3 (da) | 2018-01-29 |
Family
ID=36227798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (enExample) |
| EP (7) | EP3332789B1 (enExample) |
| JP (7) | JP5795456B2 (enExample) |
| KR (1) | KR20070091662A (enExample) |
| AR (1) | AR052830A1 (enExample) |
| AU (2) | AU2005318190B2 (enExample) |
| BR (1) | BRPI0517132B8 (enExample) |
| CA (2) | CA2588966C (enExample) |
| CY (3) | CY1112614T1 (enExample) |
| DK (3) | DK4070800T3 (enExample) |
| EA (1) | EA015799B1 (enExample) |
| ES (2) | ES2921858T3 (enExample) |
| FI (1) | FI4070800T3 (enExample) |
| FR (1) | FR18C1008I2 (enExample) |
| HR (1) | HRP20120228T1 (enExample) |
| HU (3) | HUE059133T2 (enExample) |
| IL (2) | IL183930A0 (enExample) |
| LT (3) | LT4070800T (enExample) |
| LU (1) | LUC00064I2 (enExample) |
| MX (1) | MX2007007610A (enExample) |
| NO (1) | NO20073813L (enExample) |
| PL (4) | PL2805723T3 (enExample) |
| SG (1) | SG160391A1 (enExample) |
| SI (3) | SI2805723T1 (enExample) |
| WO (1) | WO2006067141A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4070800T3 (da) | 2004-12-22 | 2025-01-02 | Merck Serono Sa | Cladribinkur til behandling af multipel sklerose |
| AU2007253254B2 (en) | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| TWI869330B (zh) * | 2017-11-24 | 2025-01-11 | 德商馬克專利公司 | 用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程 |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| ES2182920T3 (es) | 1994-12-22 | 2003-03-16 | Ortho Pharma Corp | Formulaciones solubles de 2-cloro02'-deoxiadenosina. |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| AU2003275267A1 (en) | 2002-09-25 | 2004-04-19 | Brigham Young University, Technology Transfer Office | Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| KR20060002758A (ko) * | 2003-02-25 | 2006-01-09 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 탈수초 질환에서 리바비린과 인터페론 베타의 병용 |
| CA2520523C (en) | 2003-03-28 | 2011-10-11 | Ivax Corporation | Oral formulations of cladribine |
| CN101912615B (zh) | 2003-03-28 | 2013-03-27 | 阿莱斯贸易有限公司 | 用于改善的经口和透粘膜输送的克拉屈滨制剂 |
| DK4070800T3 (da) | 2004-12-22 | 2025-01-02 | Merck Serono Sa | Cladribinkur til behandling af multipel sklerose |
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
| WO2007090393A3 (de) | Pharmazeutische zubereitung auf basis vom mikrotabletten | |
| IL177283A (en) | Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| WO2009055006A8 (en) | Deuterated darunavir | |
| WO2007146248A3 (en) | Stable laquinimod preparations | |
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| WO2012004706A3 (en) | Chemical compounds | |
| WO2009137391A3 (en) | Benzene sulfonamide thiazole and oxazole compounds | |
| LTC1781298I2 (lt) | Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui | |
| WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
| WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
| NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| WO2008073863A3 (en) | Preparation and utility of substituted allylamines | |
| WO2008004100A9 (en) | Therapeutic compounds | |
| WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
| WO2007116297A3 (en) | Use of aminapthone for the preparation of a medicament for treating arteriophaties | |
| NO20065898L (no) | 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner | |
| BRPI0618370A2 (pt) | formulação aerossol de medicamento, uso do mesmo e kit de inalação | |
| WO2008063284A3 (en) | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | |
| WO2006055663A3 (en) | The use of novel antibacterial compounds | |
| WO2005107717A8 (en) | Oral dosage form for the extended release of biguanide and sulfonylurea | |
| WO2007066200A3 (en) | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |